Institution
Autonomous University of Barcelona
Education•Cerdanyola del Vallès, Spain•
About: Autonomous University of Barcelona is a education organization based out in Cerdanyola del Vallès, Spain. It is known for research contribution in the topics: Population & Context (language use). The organization has 37833 authors who have published 80514 publications receiving 2321142 citations. The organization is also known as: Universitat Autònoma de Barcelona & Computer Vision Center.
Topics: Population, Context (language use), Medicine, Cancer, Transplantation
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this article, it was shown that the proposed Higgsless models in 5D do not provide a viable description of electroweak symmetry breaking in their full range of parameters, when calculable.
596 citations
••
University College London1, Mayo Clinic2, Vita-Salute San Raffaele University3, University of Toronto4, Cleveland Clinic5, University of Ottawa6, University of Pennsylvania7, University College Dublin8, Johns Hopkins University9, University of Basel10, Kyushu University11, Icahn School of Medicine at Mount Sinai12, National Institutes of Health13, Autonomous University of Barcelona14, University of Vermont15, National Multiple Sclerosis Society16, VU University Amsterdam17
TL;DR: This paper developed guidelines for MS differential diagnosis, focusing on exclusion of potential MS mimics, diagnosis of common initial isolated clinical syndromes, and differentiating between MS and non-MS idiopathic inflammatory demyelinating diseases.
Abstract: Background and objectivesDiagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings A systematic process for exclusion of alternative diagnoses has not been defined An International Panel of MS experts developed consensus perspectives on MS differential diagnosisMethodsUsing available literature and consensus, we developed guidelines for MS differential diagnosis, focusing on exclusion of potential MS mimics, diagnosis of common initial isolated clinical syndromes, and differentiating between MS and non-MS idiopathic inflammatory demyelinating diseasesResultsWe present recommendations for 1) clinical and paraclinical red flags suggesting alternative diagnoses to MS; 2) more precise definition of “clinically isolated syndromes” (CIS), often the first presentations of MS or its alternatives; 3) algorithms for diagnosis of three common CISs related to MS in the optic nerves, brainstem, and spinal cord; and 4) a classification schem
596 citations
••
TL;DR: How well-established risk factors for CVD can originate from inflammation in other tissues is discussed, and possible mechanistic links between skin inflammation and increased risks of obesity or metabolic alterations and CVD are considered.
593 citations
••
TL;DR: The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) as discussed by the authors compared the efficacy and safety of 24 weeks of treatment with the fusion inhibitor enfuvirtide in combination with an optimized background antiretroviral regimen with the efficacy of the optimized background regimen alone.
Abstract: Background The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) compared the efficacy and safety of 24 weeks of treatment with the fusion inhibitor enfuvirtide in combination with an optimized background antiretroviral regimen with the efficacy and safety of the optimized background regimen alone. Methods The patients had previous treatment with each of the three classes of antiretroviral drugs, documented resistance to each class, or both and a plasma level of human immunodeficiency virus type 1 (HIV-1) RNA of at least 5000 copies per milliliter. They were randomly assigned in a 2:1 ratio to receive either enfuvirtide (90 mg twice daily) plus a background regimen optimized with the aid of resistance testing (enfuvirtide group) or the background regimen alone (control group). Results Of the 512 patients who underwent randomization, 335 in the enfuvirtide group and 169 in the control group received at least one dose of study medication and had at least one follow-up measurement of plasma HIV-1 RNA. The med...
592 citations
••
TL;DR: The incidence of candidemia and prevalence of fluconazole resistance are similar to other European countries, indicating that routine antifungal susceptibility testing is not warranted.
Abstract: We conducted population-based surveillance for Candida bloodstream infections in Spain to determine its incidence, the extent of antifungal resistance, and risk factors for mortality. A case was defined as the first positive blood culture for any Candida spp. in a resident of Barcelona, from 1 January 2002 to 31 December 2003. We defined early mortality as occurring between days 3 to 7 after candidemia and late mortality as occurring between days 8 to 30. We detected 345 cases of candidemia, for an average annual incidence of 4.3 cases/100,000 population, 0.53 cases/1,000 hospital discharges, and 0.73 cases/10,000 patient-days. Outpatients comprised 11% of the cases, and 89% had a central venous catheter (CVC) at diagnosis. Overall mortality was 44%. Candida albicans was the most frequent species (51% of cases), followed by Candida parapsilosis (23%), Candida tropicalis (10%), Candida glabrata (8%), Candida krusei (4%), and other species (3%). Twenty-four isolates (7%) had decreased susceptibility to fluconazole (MIC ≥ 16 μg/ml). On multivariable analysis, early death was independently associated with hematological malignancy (odds ratio [OR], 3.5; 95% confidence interval [CI], 1.1 to 10.4). Treatment with antifungals (OR, 0.05; 95% CI, 0.01 to 0.2) and removal of CVCs (OR, 0.3; 95% CI, 0.1 to 0.9) were protective factors for early death. Receiving adequate treatment, defined as having CVCs removed and administration of an antifungal medication (OR, 0.2; 95% CI, 0.08 to 0.8), was associated with lower odds of late mortality; intubation (OR, 7.5; 95% CI, 2.6 to 21.1) was associated with higher odds. The incidence of candidemia and prevalence of fluconazole resistance are similar to other European countries, indicating that routine antifungal susceptibility testing is not warranted. Antifungal medication and catheter removal are critical in preventing mortality.
592 citations
Authors
Showing all 38202 results
Name | H-index | Papers | Citations |
---|---|---|---|
Adrian L. Harris | 170 | 1084 | 120365 |
Yang Gao | 168 | 2047 | 146301 |
Alvaro Pascual-Leone | 165 | 969 | 98251 |
David R. Jacobs | 165 | 1262 | 113892 |
Donald G. Truhlar | 165 | 1518 | 157965 |
J. S. Lange | 160 | 2083 | 145919 |
Joseph Wang | 158 | 1282 | 98799 |
José Baselga | 156 | 707 | 122498 |
Stephen J. Chanock | 154 | 1220 | 119390 |
Michael A. Matthay | 151 | 998 | 98687 |
David D'Enterria | 150 | 1592 | 116210 |
G. Eigen | 148 | 2188 | 117450 |
Inkyu Park | 144 | 1767 | 109433 |
Teruki Kamon | 142 | 2034 | 115633 |
Detlef Weigel | 142 | 516 | 84670 |